(Q36135843)

English

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

V Dieras

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

B Chevallier

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

P Kerbrat

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

I Krakowski

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

H Roche

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J L Misset

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M A Lentz

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

N Azli

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M Murawsky

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A Riva

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

P Pouillart

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

P Fumoleau

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 August 1996

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

74

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

650-656

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1996.416

0 references

ABC of breast diseases. Breast cancer--epidemiology, risk factors and genetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 October 2017

Present status of anthracyclines in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 October 2017

Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 October 2017

Breast cancer (1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 October 2017

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 July 2018

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 July 2018

Phase I trial of Taxotere: five-day schedule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074661

2 July 2018

Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Confidence intervals for reporting results of clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer in the European community and its member states

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coping with toxicities of docetaxel (Taxotere)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/8761385

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1996.416

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36135843&oldid=1981086965"